Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 21:S0166-2236(25)00138-9.
doi: 10.1016/j.tins.2025.06.008. Online ahead of print.

Triggering ferroptosis in neurodegenerative diseases

Affiliations
Review

Triggering ferroptosis in neurodegenerative diseases

Triet P M Nguyen et al. Trends Neurosci. .

Abstract

Neuronal death is a defining feature of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and motor neuron diseases, and is accordingly a priority drug target. Among the various cell death pathways, ferroptosis, a form of regulated necrosis driven by iron-dependent lipid peroxidation, has emerged as a prominent candidate underlying neurodegeneration. Despite its potential significance, putative triggers initiating lipid peroxidation cascades that lead to ferroptosis in neurodegenerative diseases remain poorly characterized. This poses significant challenges for developing targeted and disease-specific therapies. We review evidence of ferroptosis in neurodegenerative diseases and examine potential disease-relevant triggers of ferroptosis. We propose that ferroptosis, rather than being initiated by a single triggering event, emerges due to a cumulative erosion of anti-ferroptosis defense systems. This process is likely driven by context-dependent interplay between common hallmarks of neurodegenerative diseases, including neuroinflammation, protein aggregation, mitochondrial dysfunction, altered lipid metabolism, and iron accumulation.

Keywords: iron accumulation; lipid metabolism; mitochondrial dysregulation; neuroinflammation; oxidative stress; protein aggregates.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.I.B. is a shareholder in Alterity Ltd and Cogstate Ltd, and has a profit share arrangement with Collaborative Medicinal Development LLC. He has received travel and speaker funds from Novo Nordisk. The other authors declare no competing interests.

LinkOut - more resources